Turn Therapeutics Inc. filed a Form S-3 registration statement with the SEC on November 9, 2026, registering up to 25,362,950 shares of common stock for resale by selling stockholders, while also converting two prior Form S-1 registration statements into a single shelf registration.
Key Highlights
- Total shares registered: Up to 25,362,950 shares of common stock, par value $0.0001 per share, are being registered for resale by selling stockholders.
- Three tranches: The shares consist of up to 17,868,760 shares originally registered on Registration Statement I, up to 6,621,190 shares originally registered on Registration Statement II, and 873,000 newly registered shares.
- GEM purchase facility: Under the GEM Purchase Agreement dated August 29, 2025, the company may issue and sell shares to GEM with an aggregate purchase price limit of $85,000,000.
- GEM Warrant exercised: On August 13, 2026, GEM exercised a warrant for 1,192,207 shares on a cashless basis, resulting in the issuance of 579,664 shares of common stock.
- Commitment fee shares: On October 29, 2025, the company issued GEM 161,905 shares as a commitment fee, representing $850,000 divided by $5.25 per share.
- Company classification: Turn Therapeutics is identified in the filing as a non-accelerated filer, smaller reporting company, and emerging growth company.
Turn Therapeutics Consolidates Prior S-1 Registrations Into S-3 Shelf Offering
According to the filing, Turn Therapeutics Inc. submitted this Form S-3 registration statement on November 9, 2026, primarily to register the offer and resale of up to 25,362,950 shares of its common stock by named selling stockholders. The filing also serves to convert two previously effective Form S-1 registration statements - Registration Statement I (No. 333-289972, effective September 30, 2025) and Registration Statement II (No. 333-290800, effective October 29, 2025) - into a single S-3 shelf registration, pursuant to Rule 429 under the Securities Act of 1933.
The company disclosed that the aggregate shares are drawn from three sources: 17,868,760 shares originally covered by Registration Statement I; 6,621,190 shares held by GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (collectively, "GEM"), originally covered by Registration Statement II; and 873,000 additional shares being registered for the first time in this filing. The GEM shares relate to an Amended and Restated Share Purchase Agreement dated August 29, 2025, as further amended by a side letter dated September 24, 2025, under which the company may draw down shares up to an $85,000,000 aggregate purchase price limit at its sole discretion. The company's common stock commenced trading on the Nasdaq Global Market (NASDAQ:TTRX) by way of a direct listing on October 8, 2025, the filing stated.
The filing also disclosed that on August 13, 2026, GEM exercised a warrant to purchase 1,192,207 shares on a full cashless basis, with the company issuing 579,664 shares as a result. The original warrant was issued on the October 8, 2025 listing date at an exercise price of $5.03 per share. Additionally, the company issued 161,905 commitment fee shares to GEM on October 29, 2025, calculated as the $850,000 commitment fee divided by $5.25 per share. The prospectus is preliminary and subject to completion, and the securities may not be sold until the registration statement becomes effective, according to the filing.
What Was Disclosed
Turn Therapeutics filed a Form S-3 on November 9, 2026, registering up to 25,362,950 resale shares for selling stockholders, consolidating two prior S-1 registration statements, and disclosing details of its GEM share purchase facility, warrant exercise, and commitment fee share issuance.




Please wait processing your request...